Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
J Immunother Cancer ; 9(7)2021 07.
Artigo em Inglês | MEDLINE | ID: mdl-34215690

RESUMO

BACKGROUND: Resistance to an immune checkpoint inhibitor (ICI) is a major obstacle in cancer immunotherapy. The causes of ICI resistance include major histocompatibility complex (MHC)/histocompatibility locus antigen (HLA) class I loss, neoantigen loss, and incomplete antigen presentation. Elimination by natural killer (NK) cells would be expected to be an effective strategy for the treatment of these ICI-resistant tumors. We previously demonstrated that a lipid nanoparticle containing a stimulator of an interferon gene (STING) agonist (STING-LNP) efficiently induced antitumor activity via the activation of NK cells. Thus, we evaluated the potential of reducing ICI resistance by STING-LNPs. METHODS: Lung metastasis of a B16-F10 mouse melanoma was used as an anti-programmed cell death 1 (anti-PD-1)-resistant mouse model. The mice were intravenously injected with the STING-LNP and the mechanism responsible for the improvement of anti-PD-1 resistance by the STING-LNPs was analyzed by RT-qPCR and flow cytometry. The dynamics of STING-LNP were also investigated. RESULTS: Although anti-PD-1 monotherapy failed to induce an antitumor effect, the combination of the STING-LNP and anti-PD-1 exerted a synergistic antitumor effect. Our results indicate that the STING-LNP treatment significantly increased the expression of CD3, CD4, NK1.1, PD-1 and interferon (IFN)-γ in lung metastases. This change appears to be initiated by the type I IFN produced by liver macrophages that contain the internalized STING-LNPs, leading to the systemic activation of NK cells that express PD-1. The activated NK cells appeared to produce IFN-γ, resulting in an increase in the expression of the PD ligand 1 (PD-L1) in cancer cells, thus leading to a synergistic antitumor effect when anti-PD-1 is administered. CONCLUSIONS: We provide a demonstration to show that a STING-LNP treatment can overcome PD-1 resistance in a B16-F10 lung metastasis model. The mechanism responsible for this indicates that NK cells are activated by stimulating the STING pathway which, in turn, induced the expression of PD-L1 on cancer cells. Based on the findings reported herein, the STING-LNP represents a promising candidate for use in combination therapy with anti-PD-1-resistant tumors.


Assuntos
Células Matadoras Naturais/metabolismo , Lipossomos/metabolismo , Neoplasias Pulmonares/secundário , Melanoma Experimental/complicações , Proteínas de Membrana/uso terapêutico , Nanopartículas/metabolismo , Animais , Feminino , Humanos , Proteínas de Membrana/farmacologia , Camundongos , Metástase Neoplásica
2.
Nat Commun ; 6: 7802, 2015 Jul 21.
Artigo em Inglês | MEDLINE | ID: mdl-26193821

RESUMO

Lamina propria (LP) macrophages are constantly exposed to commensal bacteria, and are refractory to those antigens in an interleukin (IL)-10-dependent fashion. However, the mechanisms that discriminate hazardous invasion by bacteria from peaceful co-existence with them remain elusive. Here we show that CD169(+) macrophages reside not at the villus tip, but at the bottom-end of the LP microenvironment. Following mucosal injury, the CD169(+) macrophages recruit inflammatory monocytes by secreting CCL8. Selective depletion of CD169(+) macrophages or administration of neutralizing anti-CCL8 antibody ameliorates the symptoms of experimentally induced colitis in mice. Collectively, we identify an LP-resident macrophage subset that links mucosal damage and inflammatory monocyte recruitment. Our results suggest that CD169(+) macrophage-derived CCL8 serves as an emergency alert for the collapse of barrier defence, and is a promising target for the suppression of mucosal injury.


Assuntos
Quimiocina CCL8/metabolismo , Colite/imunologia , Colo/imunologia , Macrófagos/metabolismo , Monócitos/fisiologia , Animais , Colite/induzido quimicamente , Sulfato de Dextrana , Feminino , Imunidade nas Mucosas , Camundongos , Mucosa/imunologia , Lectina 1 Semelhante a Ig de Ligação ao Ácido Siálico/metabolismo
3.
J Pharmacol Sci ; 123(2): 140-6, 2013.
Artigo em Inglês | MEDLINE | ID: mdl-24096834

RESUMO

Electrophysiological studies were performed to determine whether serotonergic modulation in the nucleus accumbens (NAcc) was affected after repeated methamphetamine (MAP) administration. NAcc slices (400 µm) from Wistar rats administered MAP (5 mg/kg) or saline once daily for 5 days were prepared 1, 5, or 10 days after the final injection. Population spikes (PS) induced by local stimulation of NAcc were recorded. PS inhibition by serotonin was significantly attenuated in the MAP group at 5 days but did not differ at 1 or 10 days. We next analyzed the effects of serotonin receptor subtype (5-HT1A,2,3,4,6,7)-selective agonists of PS. Differences between saline and MAP groups in 5-HT1A,2,3,4,6 receptor agonist-induced changes of PS were small or not significant. Interestingly, 5-HT7 receptor agonists significantly enhanced PS in the MAP group. Changes in the secondary messenger system related to 5-HT7 receptors were also investigated. Adenylate cyclase activator-induced PS enhancements were significantly larger in the MAP group. However, dibutyryl-cAMP-induced PS enhancement was not significantly different. In conclusion, 5-HT-induced inhibition of PS in NAcc was attenuated 5 days after repeated MAP treatment: the change in the effect of 5-HT was probably due to enhancement of the excitatory modulation via the 5-HT7 receptor with adenylate cyclase signal transduction systems.


Assuntos
Adenilil Ciclases/fisiologia , Fenômenos Eletrofisiológicos/efeitos dos fármacos , Metanfetamina/farmacologia , Núcleo Accumbens/efeitos dos fármacos , Receptores de Serotonina/fisiologia , Antagonistas da Serotonina , Serotonina/farmacologia , Transdução de Sinais/efeitos dos fármacos , Transdução de Sinais/fisiologia , Animais , Ativadores de Enzimas/farmacologia , Técnicas In Vitro , Masculino , Metanfetamina/administração & dosagem , Inibição Neural/efeitos dos fármacos , Núcleo Accumbens/fisiologia , Ratos , Ratos Wistar , Sistemas do Segundo Mensageiro/fisiologia , Serotonina/fisiologia , Agonistas do Receptor de Serotonina/farmacologia , Fatores de Tempo
4.
Nihon Ishinkin Gakkai Zasshi ; 50(1): 9-13, 2009.
Artigo em Japonês | MEDLINE | ID: mdl-19194054

RESUMO

The fungicidal activities of the thiocarbamate antifungal agent liranaftate were compared to those of luliconazole, amorolfine hydrochloride and ketoconazole against twelve stock strains of three species of dermatophytes. The MICs of 0.001-0.009 microg/ml of luliconazole against Trichophyton rubrum (n=6)were the lowest among the agents tested, but its MCCs were considerably higher. Consequently, the antifungal potency of luliconazole was considered fungistatic. In contrast to this, the MCCs of 0.009-0.039 microg/ml of liranaftate against T. rubrum were the lowest and similar to its MICs. These results showed that liranaftate was fungicidal. All antifungals except ketoconazole tended to be fungicidal against both T. mentagrophytes (n=3)and Microsporum gypseum (n=3). In time-kill studies, liranaftate showed the greatest decrease to a below detection limit in viable counts of T. rubrum. The degree of killing of the strain by amorolfine was not greater than that seen by liranaftate, and little reduction of the viable counts by luliconazole and ketoconazole was observed irrespective of concentrations of the agents. Conversely, there were no differences among four agents in fungicidal activities against T.mentagrophytes. The killing activities of liranaftate against M. gypseum were also higher than those of comparable agents, as true of T. rubrum described above. In this study we found that it was harder to kill T. rubrum than other dermatophytes. Therefore, liranaftate with its potent fungicidal activities was suggested an efficacious agent for the treatment of dermatophytes.


Assuntos
Antifúngicos/farmacologia , Arthrodermataceae/efeitos dos fármacos , Naftalenos/farmacologia , Piridinas/farmacologia , Tiocarbamatos/farmacologia , Imidazóis/farmacologia , Cetoconazol/farmacologia , Morfolinas/farmacologia , Trichophyton/efeitos dos fármacos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...